Abstract 5893: Analgesic use and renal cell carcinoma incidence and survival: Results from three prospective cohort studies. Read more about Abstract 5893: Analgesic use and renal cell carcinoma incidence and survival: Results from three prospective cohort studies.
Abstract 3353: Discovery and validation of orphan noncoding RNA profiles across multiple cancers in TCGA and two independent cohorts. Read more about Abstract 3353: Discovery and validation of orphan noncoding RNA profiles across multiple cancers in TCGA and two independent cohorts.
Abstract 3808: Spatially resolved transcriptomics of cellular architecture in EGFR-mutated lung cancer. Read more about Abstract 3808: Spatially resolved transcriptomics of cellular architecture in EGFR-mutated lung cancer.
Abstract 3625: Clonal architecture and evolution of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing. Read more about Abstract 3625: Clonal architecture and evolution of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing.
Abstract 3621: 3D spatial sampling and integrated omics reveal sources and patterning of intratumoral heterogeneity in glioblastoma. Read more about Abstract 3621: 3D spatial sampling and integrated omics reveal sources and patterning of intratumoral heterogeneity in glioblastoma.
Abstract 3420: Tgfbm3b is a natural germline genetic variant that modifies anti-tumor responses to anti-PD-1 immunotherapy through its action on the tumor microenvironment. Read more about Abstract 3420: Tgfbm3b is a natural germline genetic variant that modifies anti-tumor responses to anti-PD-1 immunotherapy through its action on the tumor microenvironment.
Abstract LB516A: The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms. Read more about Abstract LB516A: The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms.
Abstract LB084: AXL as a therapeutic target in adenoid cystic carcinoma: preclinical evaluation of AXL targeting antibody-drug conjugate (ADCT-601). Read more about Abstract LB084: AXL as a therapeutic target in adenoid cystic carcinoma: preclinical evaluation of AXL targeting antibody-drug conjugate (ADCT-601).
Abstract 1446: Genetic risk factors for the development of multiple primary cancers. Read more about Abstract 1446: Genetic risk factors for the development of multiple primary cancers.
Abstract 1441: Genetic determinants of PSA levels improve prostate cancer screening. Read more about Abstract 1441: Genetic determinants of PSA levels improve prostate cancer screening.
